Drug
SB27
SB27 is a pharmaceutical drug with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
Ph phase_1
1
50%
Ph phase_3
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
active_not_recruiting2100%
Recent Activity
2 active trials
Showing 2 of 2
active_not_recruitingphase_1
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
NCT06268613
active_not_recruitingphase_3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT06348199
Clinical Trials (2)
Showing 2 of 2 trials
NCT06268613Phase 1
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
NCT06348199Phase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2